Novavax upgraded by BofA Securities with a new price target

5/10/24 1:12:36 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

BofA Securities upgraded Novavax from Underperform to Neutral and set a new price target of $12.00 from $4.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NVAX

Date	Price Target	Rating	Analyst
6/17/2025	$6.00	Sell	Citigroup
2/28/2025	$19.00	Buy	BTIG Research
7/30/2024	$8.00	Neutral → Underweight	JP Morgan
5/10/2024	$4.00 → $12.00	Underperform → Neutral	BofA Securities
5/10/2024		Underweight → Neutral	JP Morgan
8/9/2023	$15.00	Neutral → Buy	B. Riley Securities
4/20/2023	$55.00 → $10.00	Outperform → Market Perform	TD Cowen
3/1/2023	$29.00 → $10.00	Buy → Neutral	B. Riley Securities